Latest Breaking News On - Praxis precision medicines - Page 7 : comparemela.com
Find insight on Praxis Precision Medicines in the latest Market Talks covering the Health Care sector.
Health-care
Praxis-precision-medicines
Market-talks
Despite numerous marketed anti-seizure medications in the U.S., patients with epilepsy continue to experience breakthrough seizures and tolerability issues compounded with drug interactions and side effects, leaving room for companies like Praxis Precision Medicines Inc. to fill treatment gaps. The Boston-based company presented phase IIa proof-of-concept data March 26 showing that in an evaluation of photo paroxysmal response, its once-daily oral small-molecule treatment, PRAX-628, resulted in a complete response in three epilepsy patients receiving 45 mg of the drug and four patients receiving 15 mg for a combined complete response rate of 88%. One patient in the 15-mg group experienced a partial response.
Boston
Massachusetts
United-states
Praxis-precision-medicines-inc
Praxis-precision-medicines